15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Simulation of dosimetry impact of 4DCT uncertainty in 4D dose calculation for lung SBRT

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Due to the heterogeneity of patient’s individual respiratory motion pattern in lung stereotactic body radiotherapy (SBRT), treatment planning dose assessment using a traditional four-dimensional computed tomography (4DCT_traditional) images based on a uniform breathing curve may not represent the true treatment dose delivered to the patient. The purpose of this study was to evaluate the accumulated dose discrepancy between based on the 4DCT_traditional and true 4DCT (4DCT_true) that incorporated with the patient’s real entire breathing motion. The study also explored a novel 4D robust planning strategy to compensate for such heterogeneity respiratory motion uncertainties.

          Methods

          Simulated and measured patient specific breathing curves were used to generate 4D targets motion CT images. Volumetric-modulated arc therapy (VMAT) was planned using two arcs. Accumulated dose was obtained by recalculating the plan dose on each individual phase image and then deformed the dose from each phase image to the reference image. The “4 D dose” ( D 4 D ) and “true dose” (D true) were the accumulated dose based on the 4DCT_traditional and 4DCT_true respectively. The average worse case dose discrepancy ( \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline{\Delta D} $$\end{document} ) between D 4 D and D true in all treatment fraction was calculated to evaluate dosimetric /planning parameters and correlate them with the heterogeneity of respiratory-induced motion patterns. A novel 4D robust optimization strategy for VMAT (4D Ro-VMAT) based on the probability density function(pdf) of breathing curve was proposed to improve the target coverage in the presence of heterogeneity respiratory motion. The data were assessed with a paired t-tests.

          Results

          With increasing breathing amplitude from 5 to 20 mm, target \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline{\Delta {D}_{99}} $$\end{document} , \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline{\Delta {D}_{95}} $$\end{document} increased from 1.59,1.39 to 10.15%,8.66% respectively. When the standard deviation of breathing amplitude increased from 15 to 35% of the mean amplitude, \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline{\Delta {D}_{99}} $$\end{document} , \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$ \overline{\Delta {D}_{95}} $$\end{document} increased from 4.06,3.48 to 10.25%,6.63% respectively. The 4D Ro-VMAT plan significantly improve the target dose compared to VMAT plan.

          Conclusion

          When the breathing curve amplitude is more than 10 mm and standard deviation of amplitude is higher than 25% of mean amplitude, special care is needed to choose an appropriated dose accumulation approach to evaluate lung SBRT plan target coverage robustness. The proposed 4D Ro_VMAT strategy based on the pdf of patient specific breathing curve could effectively compensate such uncertainties.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

          Hypofractionated stereotactic radiotherapy (HypoFXSRT) has recently been used for the treatment of small lung tumors. We retrospectively analyzed the treatment outcome of HypoFXSRT for stage I non-small cell lung cancer (NSCLC) treated in a Japanese multi-institutional study. This is a retrospective study to review 257 patients with stage I NSCLC (median age, 74 years: 164 T1N0M0, 93 T2N0M0) were treated with HypoFXSRT alone at 14 institutions. Stereotactic three-dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. A total dose of 18 to 75 Gy at the isocenter was administered in one to 22 fractions. The median calculated biological effective dose (BED) was 111 Gy (range, 57-180 Gy) based on alpha/beta = 10. During follow-up (median, 38 months), pulmonary complications of above grade 2 arose in 14 patients (5.4%). Local progression occurred in 36 patients (14.0%), and the local recurrence rate was 8.4% for a BED of 100 Gy or more compared with 42.9% for less than 100 Gy (p < 0.001). The 5-year overall survival rate of medically operable patients was 70.8% among those treated with a BED of 100 Gy or more compared with 30.2% among those treated with less than 100 Gy (p < 0.05). Although this is a retrospective study, HypoFXSRT with a BED of less than 180 Gy was almost safe for stage I NSCLC, and the local control and overall survival rates in 5 years with a BED of 100 Gy or more were superior to the reported results for conventional radiotherapy. For all treatment methods and schedules, the local control and survival rates were better with a BED of 100 Gy or more compared with less than 100 Gy. HypoFXSRT is feasible for curative treatment of patients with stage I NSCLC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

            The 50-month results of a prospective Phase II trial of stereotactic body radiation therapy (SBRT) in medically inoperable patients are reported. A total of 70 medically inoperable patients had clinically staged T1 (34 patients) or T2 (36 patients) ( 20 cc) did not significantly impact survival: MS was 36.9 months (95% CI, 18.1-42.9), 34.0 (95% CI, 16.9-57.1), 32.8 (95% CI, 21.3-57.8), and 21.4 months (95% CI, 17.8-41.6), respectively (p = 0.712). There was no significant survival difference between patients with peripheral vs. central tumors (MS 33.2 vs. 24.4 months, p = 0.697). Grade 3 to 5 toxicity occurred in 5 of 48 patients with peripheral lung tumors (10.4%) and in 6 of 22 patients (27.3%) with central tumors (Fisher's exact test, p = 0.088). Based on our study results, use of SBRT results in high rates of local control in medically inoperable patients with Stage I NSCLC.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Incidence of local recurrence and second primary tumors in resected stage I lung cancer

                Bookmark

                Author and article information

                Contributors
                liugang9910@163.com
                00009924@whu.edu.cn
                Xuanfeng.Ding@beaumont.edu
                Xiaoqiang.li@beaumont.edu
                qihongshao@whu.edu.cn
                Yuenan.wang@yahoo.com
                80881525@qq.com
                +8613317101142 , csp6606@sina.com
                Journal
                Radiat Oncol
                Radiat Oncol
                Radiation Oncology (London, England)
                BioMed Central (London )
                1748-717X
                8 January 2019
                8 January 2019
                2019
                : 14
                : 1
                Affiliations
                [1 ]ISNI 0000 0001 2331 6153, GRID grid.49470.3e, Key Laboratory of Artificial Micro- and Nano- structures of Ministry of Education and Center for Electronic Microscopy, School of Physics and Technology, , Wuhan University, ; Wuhan, 430072 China
                [2 ]ISNI 0000 0004 0368 7223, GRID grid.33199.31, Cancer Center, Union Hospital, Tongji Medical College, , Huazhong University of Science and Technology, ; Wuhan, 430022 China
                [3 ]ISNI 0000 0001 2331 6153, GRID grid.49470.3e, School of Mathematics and Statistics, , Wuhan University, ; Wuhan, 430072 China
                [4 ]ISNI 0000 0004 0460 1081, GRID grid.461921.9, Proton Therapy Center Beaumont Health, ; Royal Oak, MI 48074 USA
                [5 ]Wuhan Zhongyuan Electronics Group Co. LTD, Wuhan, 430205 China
                [6 ]ISNI 0000 0004 0632 3230, GRID grid.459409.5, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, ; Shenzhen, 518000 China
                Article
                1191
                10.1186/s13014-018-1191-y
                6323842
                30621744
                47ba8f94-2fb2-4d6c-97a7-a956b9d71189
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 19 June 2018
                : 21 November 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: No. 10875092
                Award ID: No.31271511
                Funded by: Natural Science Foundation of Hubei Province of China
                Award ID: No.2012KB04449
                Funded by: the Natural Science Foundation of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
                Award ID: No.02.03.2017-289
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2019

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article